# Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

> **NCT07739888** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 2500 (estimated)

## Conditions studied

- Atrial Fibrillation (AF)

## Interventions

- **BIOLOGICAL:** Abelacimab

## Key facts

- **NCT ID:** NCT07739888
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-12-30
- **Primary completion:** 2030-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 2500 (ESTIMATED)
- **Last updated:** 2026-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07739888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07739888, "Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07739888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*